Seres Therapeutics Crecimiento futuro

Future controles de criterios 0/6

Se prevé que los ingresos de Seres Therapeutics disminuyan en un 22.8% al año, mientras que se espera que sus beneficios anuales crezcan en un 30.4% al año. Se prevé que el BPA crezca en un 38.2% anual. Se prevé que la rentabilidad financiera sea de -101.3% en 3 años.

Información clave

30.4%

Tasa de crecimiento de los beneficios

38.2%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	21.3%
Tasa de crecimiento de los ingresos	-22.8%
Rentabilidad financiera futura	-101.3%
Cobertura de analistas	Good
Última actualización	09 Apr 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Benign Growth For Seres Therapeutics, Inc. (NASDAQ:MCRB) Underpins Stock's 30% Plummet

Mar 23

Seres Therapeutics' Balancing Act: Breakthrough IP And Financing Concerns

Jan 30

Lacklustre Performance Is Driving Seres Therapeutics, Inc.'s (NASDAQ:MCRB) 30% Price Drop

Dec 18

Lacklustre Performance Is Driving Seres Therapeutics, Inc.'s (NASDAQ:MCRB) 27% Price Drop

Aug 31

Some Seres Therapeutics, Inc. (NASDAQ:MCRB) Analysts Just Made A Major Cut To Next Year's Estimates

Mar 02

Rock star Growth Puts Seres Therapeutics (NASDAQ:MCRB) In A Position To Use Debt

Dec 27

Seres Therapeutics Molecular Data On SER-109 Looks Good

Oct 04

Seres Therapeutics: Here We Go Again

Sep 09

Is Seres Therapeutics (NASDAQ:MCRB) Weighed On By Its Debt Load?

Sep 03

Need To Know: Analysts Are Much More Bullish On Seres Therapeutics, Inc. (NASDAQ:MCRB) Revenues

Jul 03

Seres Therapeutics (MCRB) Presents At 2021 Jefferies Virtual Healthcare Conference - Slideshow

Jun 08

Seres Therapeutics gets FDA clearance for SER-155 IND trials

Jun 01

Broker Revenue Forecasts For Seres Therapeutics, Inc. (NASDAQ:MCRB) Are Surging Higher

May 20

Seres Therapeutics, Inc. 2021 Q1 - Results - Earnings Call Presentation

May 05

Is Seres Therapeutics (NASDAQ:MCRB) Using Debt In A Risky Way?

Apr 05

Previsiones de crecimiento de beneficios e ingresos

NasdaqGS:MCRB - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	52	-64	84	-127	4
12/31/2025	8	-153	-18	-176	6
12/31/2024	1	-186	-98	-185	7
12/31/2023	126	-114	-125	-117	N/A
9/30/2023	127	-141	-133	-123	N/A
6/30/2023	130	-153	-133	-123	N/A
3/31/2023	5	-265	-250	-239	N/A
12/31/2022	7	-250	-239	-229	N/A
9/30/2022	13	-231	-236	-228	N/A
6/30/2022	137	-103	-51	-40	N/A
3/31/2022	141	-87	-41	-30	N/A
12/31/2021	145	-66	-3	7	N/A
9/30/2021	155	-34	32	41	N/A
6/30/2021	30	-132	-117	-113	N/A
3/31/2021	31	-105	-101	-99	N/A
12/31/2020	33	-89	-94	-94	N/A
9/30/2020	23	-90	-90	-90	N/A
6/30/2020	29	-76	-83	-82	N/A
3/31/2020	35	-66	-69	-68	N/A
12/31/2019	35	-70	-78	-77	N/A
9/30/2019	38	-73	-50	-50	N/A
6/30/2019	40	-78	-56	-55	N/A
3/31/2019	32	-95	-70	-68	N/A
12/31/2018	28	-99	-65	-63	N/A
9/30/2018	21	-107	-99	-96	N/A
6/30/2018	35	-92	-79	-77	N/A
3/31/2018	33	-92	-80	-77	N/A
12/31/2017	32	-89	-80	-76	N/A
9/30/2017	32	-86	N/A	-76	N/A
6/30/2017	22	-97	N/A	-83	N/A
3/31/2017	22	-97	N/A	-83	N/A
12/31/2016	22	-92	N/A	44	N/A
9/30/2016	19	-86	N/A	53	N/A
6/30/2016	6	-82	N/A	53	N/A
3/31/2016	3	-67	N/A	69	N/A
12/31/2015	N/A	-55	N/A	-41	N/A
9/30/2015	N/A	-44	N/A	-33	N/A
6/30/2015	N/A	-34	N/A	-25	N/A
3/31/2015	N/A	-24	N/A	-17	N/A
12/31/2014	N/A	-18	N/A	-10	N/A
9/30/2014	N/A	-12	N/A	-8	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que MCRB siga sin ser rentable en los próximos 3 años.

Beneficios vs. Mercado: Se prevé que MCRB siga sin ser rentable en los próximos 3 años.

Beneficios de alto crecimiento: Se prevé que MCRB siga sin ser rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos de MCRB disminuyan en los próximos 3 años (-22.8% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos de MCRB disminuyan en los próximos 3 años (-22.8% al año).

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: MCRB se prevé que no sea rentable en 3 años.

Descubre empresas en crecimiento

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Seres Therapeutics Crecimiento futuro

Future controles de criterios 0/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Consensus revenue estimates decrease by 63%, EPS upgraded

No longer forecast to breakeven

Price target increased by 7.7% to US$9.02

Price target increased by 15% to US$9.80

Forecast to breakeven in 2026

Consensus EPS estimates upgraded to US$0.98 loss, revenue downgraded

Recent updates

Seres Therapeutics Receives Non-Compliance Letter from The Nasdaq Stock Market LLC Related to Nasdaq Listing Rule 5450(a)(1)

New minor risk - Market cap size

Seres Therapeutics Announces Completion of Patient Enrollment for SER-155 Phase 1B Cohort 2 Clinical Trial in Allogenic HSCT

Benign Growth For Seres Therapeutics, Inc. (NASDAQ:MCRB) Underpins Stock's 30% Plummet

Consensus revenue estimates decrease by 63%, EPS upgraded

New minor risk - Financial position

Full year 2023 earnings: EPS exceeds analyst expectations

No longer forecast to breakeven

Seres Therapeutics Appoints Marella Thorell as Executive Vice President

Price target increased by 7.7% to US$9.02

Price target increased by 15% to US$9.80

Seres Therapeutics' Balancing Act: Breakthrough IP And Financing Concerns

Seres Therapeutics Announces VOWST™ Commercial Launch Update and US FDA Fast Track Designation for SER-155

Forecast to breakeven in 2026

Lacklustre Performance Is Driving Seres Therapeutics, Inc.'s (NASDAQ:MCRB) 30% Price Drop

Consensus EPS estimates upgraded to US$0.98 loss, revenue downgraded

Price target decreased by 13% to US$8.54

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Seres Therapeutics, Inc. to Report Q3, 2023 Results on Nov 02, 2023

New minor risk - Share price stability

Lacklustre Performance Is Driving Seres Therapeutics, Inc.'s (NASDAQ:MCRB) 27% Price Drop

Consensus EPS estimates fall by 34%

Seres Therapeutics (NASDAQ:MCRB) Has Debt But No Earnings; Should You Worry?

Second quarter 2023 earnings: EPS misses analyst expectations

Second quarter 2023 earnings: EPS misses analyst expectations

Price target decreased by 7.6% to US$10.17

Seres Therapeutics, Inc. and Nestle Health Science Present Late-Breaking Data on VOWST™, a Microbiota-Based Oral Therapeutic for Prevention of Recurrence of C. Difficile Infection in Adults, at ASM Microbe 2023

Seres Therapeutics, Inc. and Nestlé Health Science Announce U.S. Commercial Availability of VOWST™

Consensus EPS estimates upgraded to US$0.96 loss

Seres Therapeutics Reports SER-155 Phase 1b Cohort 1 Results Showing Successful Drug Bacteria Engraftment and Substantial Reduction in Pathogen Domination in the Gastrointestinal Microbiome

First quarter 2023 earnings released: US$0.56 loss per share (vs US$0.61 loss in 1Q 2022)

Consensus estimates of losses per share improve by 13%

Price target decreased by 11% to US$11.00

Full year 2022 earnings: EPS and revenues miss analyst expectations

Seres Therapeutics' Investigational Ser-109 Ecospor Iv Study Data Publishes in Jama Network Open

Seres Therapeutics, Inc. Announces Initiation of Enrollment in SER-155 Phase 1B Study Cohort 2 in Individuals Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Insufficient new directors

Seres Therapeutics, Inc. Announces the Appointment of Claire M. Fraser, Ph.D., to Its Board of Directors

Is Seres Therapeutics (NASDAQ:MCRB) Weighed On By Its Debt Load?

Consensus forecasts updated

Price target increased to US$14.33

Seres Therapeutics Announces FDA Acceptance of Biologics License Application for Investigational Microbiome Therapeutic SER-109 for Recurrent C. Difficile Infection for Priority Review

Seres Therapeutics, Inc. Announces the Publication of Phase 3 Clinical Data in the Journal of the American Medical Association

Seres Therapeutics Announces Completion of Rolling BLA Submission to FDA for Investigational Microbiome Therapeutic SER-109 for Recurrent C. Difficile Infection

Estimating The Fair Value Of Seres Therapeutics, Inc. (NASDAQ:MCRB)

Seres Therapeutics: What The Market Is Missing

Consensus revenue estimates increase by 16%

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Seres Therapeutics GAAP EPS of -$0.70 misses by $0.10, revenue of $1.22M

Seres Therapeutics: The Good And The Challenging

Seres Therapeutics stock slips on $100M stock offering

Is Seres Therapeutics (NASDAQ:MCRB) Using Too Much Debt?

Seres Therapeutics: As Biotech Fades The Case For Seres Investment Strengthens

Seres Therapeutics, Inc. Announces Confirmatory Results from Investigational Microbiome Therapeutic SER-109 ECOSPOR IV Open-Label Study in Recurrent C. Difficile Infection

Seres Therapeutics Presents Phase III Results of SER-109 for Recurrent C. Difficile Infection at the Digestive Disease Week (DDW) Annual Meeting

Seres Therapeutics to Present Data on Investigational Microbiome Therapeutic Ser-109 for Recurrent C. Difficile Infection At the Digestive Disease Week (Ddw) Annual Meeting

Consensus revenue estimates fall by 64%

Price target decreased to US$17.57

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Seres Therapeutics, Inc., Annual General Meeting, Jun 22, 2022

Consensus revenue estimates fall by 30%

Seres Therapeutics Is Playing A Long Game

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Some Seres Therapeutics, Inc. (NASDAQ:MCRB) Analysts Just Made A Major Cut To Next Year's Estimates

Seres Therapeutics Appoints Paula Cloghessy as Executive Vice President, Chief People Officer

Seres Therapeutics, Inc. Announces the Publication in the New England Journal of Medicine of Data from Its Phase 3 ECOSPOR III study evaluating SER-109

Rock star Growth Puts Seres Therapeutics (NASDAQ:MCRB) In A Position To Use Debt

Seres Therapeutics, Inc. Announces Preliminary SER-287 Phase 2b ECO-RESET Study Microbiome Data Analysis

Seres Therapeutics Announces First Patient Enrolled in Phase 1B Study of SER-155